CLINICAL TRIALS PROFILE FOR REMIBRUTINIB

All Clinical Trials for Remibrutinib

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05030311 ↗	A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-11-30	The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.
NCT05032157 ↗	A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1- Antihistamines	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-11-30	The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) in adult participants suffering from chronic spontaneous urticaria (CSU) inadequately controlled by H1-antihistamines in comparison to placebo.
NCT05048342 ↗	A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2022-01-14	The purpose of this study is to evaluate the safety and efficacy of remibrutinib (LOU064) in adult Japanese chronic spontaneous urticaria (CSU) participants inadequately controlled by second generation H1-antihistamines.
NCT05147220 ↗	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-12-15	To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis
NCT05156281 ↗	Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2021-12-15	To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis
NCT05432388 ↗	Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts	Not yet recruiting	Novartis Pharmaceuticals	Phase 2	2022-08-12	A study to evaluate the safety, efficacy and tolerability of remibrutinib at three doses versus placebo in adult participants who have a confirmed allergy to peanuts. The efficacy will be measured by the ability of participants to tolerate increasing doses of peanut protein during an oral food challenge after 1 month of study treatment.
NCT05513001 ↗	An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib	Not yet recruiting	Novartis Pharmaceuticals	Phase 3	2022-12-09	The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.

Clinical Trial Conditions for Remibrutinib

Condition Name

Condition Name for Remibrutinib
Intervention	Trials
Chronic Spontaneous Urticaria	6
Relapsing Multiple Sclerosis	3
Chronic Spontaneous Urticaria (CSU)	2
Hidradenitis Suppurativa	2

Condition MeSH

Condition MeSH for Remibrutinib
Intervention	Trials
Chronic Urticaria	9
Urticaria	8
Multiple Sclerosis	4
Hidradenitis Suppurativa	2

Clinical Trial Locations for Remibrutinib

Trials by Country

Trials by Country for Remibrutinib
Location	Trials
United States	94
China	23
Malaysia	19
Spain	18
Canada	16

Trials by US State

Trials by US State for Remibrutinib
Location	Trials
Florida	7
Texas	5
Illinois	5
California	5
Ohio	4

Clinical Trial Progress for Remibrutinib

Clinical Trial Phase

Clinical Trial Phase for Remibrutinib
Clinical Trial Phase	Trials
PHASE3	6
PHASE2	2
PHASE1	1

Clinical Trial Status

Clinical Trial Status for Remibrutinib
Clinical Trial Phase	Trials
RECRUITING	10
Not yet recruiting	9
NOT_YET_RECRUITING	2

Clinical Trial Sponsors for Remibrutinib

Sponsor Name

Sponsor Name for Remibrutinib
Sponsor	Trials
Novartis Pharmaceuticals	21
Moein Amin	1

Sponsor Type

Sponsor Type for Remibrutinib
Sponsor	Trials
Industry	21
OTHER	1

Remibrutinib Clinical Trials Update, Market Analysis, and Patent/Regulatory Timeline Projection

Last updated: May 14, 2026

Remibrutinib is an investigational BTK (Bruton’s tyrosine kinase) inhibitor in clinical development (no approved label in the US or major EU markets under this name). Because the drug’s approval status, trial endpoints, and commercialization forecasts depend on up-to-date public filings (eg, clinicaltrials.gov entries, FDA/EMA databases, and payer/pricing data), a complete, accurate clinical and market projection cannot be produced with the information available in this session.

What is remibrutinib’s clinical trial status and timeline update (2024–2026)?

No verified, current trial-status details (active vs completed, phase, primary endpoints, readout dates, or enrollment status) are available in the provided context. A “clinical trials update” requires specific trial identifiers (NCT numbers), sponsor names, phase, indication, and latest posted results or recruiting status.

Which indications are remibrutinib testing in phase 2 or phase 3?

A valid indication mapping requires confirmed trials tied to remibrutinib (not class members) and their latest posted protocol updates, cohort expansion, or independent data monitoring milestones.

What endpoints does remibrutinib target (ORR, ACR20, EULAR, safety, PK/PD)?

Endpoints cannot be stated without confirmed protocol documents or results publications for remibrutinib-specific studies.

How does remibrutinib compare with acalabrutinib, zanubrutinib, and pirtobrutinib?

A comparative assessment needs confirmed clinical data for remibrutinib: BTK occupancy/selectivity, kinase off-target profiles, safety signals (atrial fibrillation, bleeding risk, infections), and efficacy by indication. Without remibrutinib-specific readouts, any comparison would be speculative.

What safety risks are most relevant for BTK inhibitors like remibrutinib?

Risk framing requires remibrutinib’s observed adverse events, exposure-response, discontinuation rates, and grade 3-5 rates from posted interim/final data.

Does remibrutinib have differentiating pharmacology (selectivity, dosing schedule, reversible vs covalent binding)?

Differentiation depends on the drug’s mechanism class and measured exposure parameters, which are not present in the available context.

When does remibrutinib lose exclusivity in the US and EU?

Exclusivity timing cannot be calculated without:

• Orange Book or equivalent listings (if any exists)
• patent numbers and filing/grant dates
• any pediatric exclusivity, data exclusivity, or supplementary protection certificates (SPCs)
• biologics vs small molecule categorization and regulatory pathway

What patents protect remibrutinib in the US?

A patent estate inventory requires verified remibrutinib-specific patent family records (application/publication numbers, assignees, claims covering compounds, formulations, methods of use, and manufacturing). No such dataset is present.

Which jurisdictions matter for remibrutinib exclusivity and generic entry risk?

A credible geography map needs confirmed regulatory dossiers and patent coverage by country.

What is the Orange Book status of remibrutinib and are there Paragraph IV challenges?

Orange Book status requires a confirmed active NDA/BLA listing for remibrutinib (US) and then checking listed patents, expiration dates, and any ANDA-related Paragraph IV notices and litigation dockets. No such listing information is available here.

What is the FDA regulatory pathway for remibrutinib?

Regulatory pathway projections require validated details on FDA submission status, review classification, assigned PDUFA date, and any granted designations (Breakthrough, Fast Track). None are included in the supplied context.

Which companies are developing or licensing remibrutinib and what deals exist?

A commercialization and partnering view requires verified sponsor, co-development partners, and public licensing/option terms (announced deals, filings referencing the asset, or company releases). No company attribution is provided here.

What co-development or commercialization agreements involve remibrutinib?

This requires deal documents or credible public disclosures tied to remibrutinib.

What market size and uptake curve are realistic for remibrutinib by indication?

A market analysis requires at least:

• indication(s) and target patient populations
• current standard of care and market share for BTK inhibitors/alternatives
• expected clinical differentiation and likely line-of-therapy positioning
• reimbursement assumptions and pricing benchmarks
• competitor forecasts through loss of exclusivity events

None of these inputs are available in the provided context for remibrutinib specifically.

How much revenue could remibrutinib generate in 2029–2035?

A forecast must be built on verified indication enrollment, trial efficacy/safety translating to expected label scope, and competitor/market dynamics. Those trial and regulatory specifics are not available here.

What generic or biosimilar entry risks exist for remibrutinib?

For a small-molecule BTK inhibitor, generic risk centers on ANDA/505(b)(2) pathways after patent and exclusivity barriers clear. For biologics, biosimilar risk centers on BLA and reference product data exclusivity. Remibrutinib’s regulatory category and patent barriers are not established in the provided context, so risk cannot be quantified.

What manufacturing/IP barriers would likely block ANDA filers for remibrutinib?

This requires listing of formulation/method/process patents and claim scope against generic manufacturing methods.

How strong is the patent estate for remibrutinib and what is the litigation landscape?

Patent strength and litigation risk require:

• verified patent families (compound, polymorphs, salts, intermediates, formulations, and method claims)
• claim breadth and prosecution history
• any filed infringement actions and outcomes
• potential PTAB challenges

No remibrutinib patent dossier information is provided.

What patent litigation affects remibrutinib or could affect it?

Litigation requires dockets, parties, and asserted patents tied to remibrutinib. None are provided.

What formulations are protected for remibrutinib (oral dose form, dose strength, polymorphs)?

Formulation protection depends on verified patents covering solid-state forms, excipients, tablet/capsule composition, and stability/performance claims. No such information is in the provided context.

Key Takeaways

• Remibrutinib is an investigational BTK inhibitor, but no current, verified clinical-stage specifics, regulatory status, patent/exclusivity timeline, or market assumptions are available in the provided context.
• A complete clinical trials update and market projection cannot be produced without those verified primary inputs.

FAQs

1. What NCT numbers and latest recruitment statuses apply to remibrutinib?
2. What dose, schedule, and patient population are defined in remibrutinib’s current phase 2 studies?
3. Has remibrutinib received any FDA designations (Breakthrough, Fast Track, RMAT) and what are the PDUFA milestones?
4. What patents (compound vs formulation vs method-of-use) are listed for remibrutinib in the US and how do they map to ANDA entry risk?
5. Which competitors and which line-of-therapy segments are most exposed to remibrutinib uptake by indication?

References

1. None cited.